DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Thibaut Mongon - 5 Johnson - 4 Kenvue - 4 J - 2 J's - 2 CNBC's - 2 Mongon - 2 Squawk - 1
Top related locs:
Kenvue New York City U.S Canada
Top related orgs:
J - 2 Kenvue Inc - 2 New York Stock Exchange - 2 Johnson - 2 CNBC - 1 RBC Capital - 1 JPMorgan - 1 Refinitiv - 1

Search resuls for: "Mongon"


13 mentions found


☆ Kenvue CEO Thibaut Mongon: We feel very good about the strength of our business model
  + stars: | 2023-10-26 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailKenvue CEO Thibaut Mongon: We feel very good about the strength of our business modelKenvue CEO Thibaut Mongon joins ‘Squawk on the Street’ to discuss the company's latest quarter, their new products in the market, and more.
Persons: Thibaut Mongon, Squawk
☆ Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
  + stars: | 2023-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J owns 89.6% of Kenvue's common stock, which amounts to more than 1.72 billion shares. The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue's common stock at a 7% discount. J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. When asked about J&J's planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC's "Squawk on the Street" that the company is "pleased with the way that the IPO has been received by shareholders."
Persons: Johnson, J, Joaquin Duato, Duato, Kenvue, J's, Thibaut Mongon, CNBC's Organizations: J Locations: Kenvue
☆ Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
  + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name health and personal care products, Kenvue CEO Thibaut Mongon said. Kenvue also noted that "private label" penetration in the consumer health product market was stable for the quarter. Those spending trends could bode well not only for Kenvue, but also for other companies in the consumer health, beauty and beverage spaces that may not see consumers trade down to cheaper products as often despite stubbornly high prices. RBC Capital analyst Nik Modi expressed confidence in Kenvue's ability to "maintain its momentum," highlighting consumer trust in the company's brands and health and personal care products overall. Meanwhile, Kenvue has gained market share, and could potentially continue to do so despite the broader environment, he noted.
Persons: Thibaut Mongon, Johnson, Mongon, Kenvue, bode, we've, Nik Modi, Modi Organizations: Kenvue Inc, New York Stock Exchange, CNBC, Johnson, J, RBC Capital Locations: Kenvue
☆ J&J spinoff Kenvue CEO on first full quarterly earnings results since IPO
  + stars: | 2023-07-20 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJ&J spinoff Kenvue CEO on first full quarterly earnings results since IPOThibaut Mongon, Kenvue CEO, joins 'Squawk on the Street' to discuss the company's quarterly earnings results, what Mongon is seeing from the consumer, and much more.
Persons: Thibaut
☆ Johnson & Johnson investors can soon swap their shares for Kenvue stock — here's what you need to know
  + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson on Thursday said its shareholders will soon be able to swap their shares for stock of Kenvue , which spun out as an independent consumer health company just two months ago. That process, also known as a split-off, will allow J&J shareholders to exchange all or a portion of their shares for Kenvue's common stock. Kenvue shares fell following the announcement Thursday, even though the company beat earnings and revenue estimates in its first quarterly report since its IPO. Previously, J&J did not disclose whether it would divest its Kenvue shares through a split-off or a spinoff. The latter would involve distributing Kenvue stock to existing J&J shareholders rather than giving them the option to exchange.
Persons: Thibaut Mongon, Paul Ruh, Johnson, J, Joseph Wolk, Wolk, J's, CNBC's, Kenvue, Goldman Sachs, JPMorgan Chase Organizations: Kenvue Inc, New York Stock Exchange, JPMorgan Locations: New York City, U.S
☆ Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO
  + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Kenvue reported second-quarter revenue and adjusted earnings that topped expectations Thursday in the consumer health company's first quarterly report since it spun out from Johnson & Johnson two months ago. But J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the spinoff's business for now. Excluding certain items, the company's adjusted earnings were 32 cents a share. The company's full-year adjusted earnings outlook is $1.26 to $1.31 per share. The company reported sales growth across its three business divisions in the second quarter.
Persons: Kenvue, Johnson, Kenvue's, Thibaut Mongon, headwinds, Mongon Organizations: Johnson, Refinitiv, Deutsche Bank Global Consumer Conference Locations: Kenvue, Canada
☆ Kenvue CEO looks to brand, product innovation to drive growth after IPO
  + stars: | 2023-05-05 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company's IPO at the New York Stock Exchange (NYSE), May 4, 2023. Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out company after its solid debut on the public market Thursday. Kenvue, spun out of Johnson & Johnson , carries a packed portfolio of widely known brands, such as Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno and J&J's namesake baby powder. But Mongon told CNBC that Kenvue's portfolio of brands has "ample opportunity" to grow. Mongon believes product innovation ultimately makes Kenvue's brands "more relevant than ever" to consumers as they better target their needs.
☆ Johnson & Johnson's consumer health unit Kenvue started trading. What it means for J&J shareholders like us
  + stars: | 2023-05-05 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +9 min
For now, it's not exactly clear how J & J will go about the second step of this divestiture. In this scenario, we would have the option to relinquish some, all or none of our J & J shares. In fact, our optimism around the breakup was a big reason we bought into J & J nearly a year ago . J & J continues to argue against claims that its baby powder and other talc products caused cancer lack merit. "Look at it as a whole company today, knowing that [roughly] 10% doesn't belong to J & J," explained Cantor Fitzgerald analyst Louise Chen, who has a buy rating and maintains a $215 price target on J & J.
☆ J&J's consumer health spinoff Kenvue opens at $25.53, a 16% jump, in public market debut
  + stars: | 2023-05-04 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson's consumer-health business, pose together during the company's IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Johnson & Johnson 's consumer health spinoff Kenvue jumped 16% in its market debut on the New York Stock Exchange Thursday, marking the biggest U.S. IPO in more than a year. Kenvue sold 172.8 million shares in an upsized deal that raised about $3.8 billion and valued the company at roughly $41 billion. "Millions of consumers around the world this morning wake up with a Kenvue product in their home," CEO Thibaut Mongon, told CNBC's "Squawk on the Street" Thursday morning ahead of the stock's debut. Mongon previously served as J&J's executive vice president and worldwide chair of consumer health.
☆ J&J spinoff Kenvue goes public
  + stars: | 2023-05-04 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJ&J spinoff Kenvue goes publicKenvue CEO Thibaut Mongon joins 'Squawk on the Street' to discuss the company's IPO, which is the largest U.S. IPO since November 2021.
☆ Johnson & Johnson to price shares of consumer spinoff Kenvue at $20 to $23 in IPO
  + stars: | 2023-04-24 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Johnson & Johnson will price shares of its consumer-health spinoff Kenvue at $20 to $23 in an initial public offering later this year, the company said in a regulatory filing Monday. J&J said it launched a roadshow for the IPO of more than 151 million shares of common stock. Kenvue estimates the IPO will generate net proceeds of around $3.15 million, the filing said. Kenvue expects to grant underwriters a 30-day option to purchase up to an additional 22.6 million shares of stock to cover any over-allotments, according to the filing. The company noted it will own 1.7 billion shares of Kenvue's common stock after the IPO, representing 91.9% of the spinoff's total shares.
☆ What to watch for as J&J gets ready to split into two separate companies next year
  + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com   time to read: +11 min
During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.
Organizations: & $
☆ Band-Aids and Tylenol will have a new name on their packages: Kenvue
  + stars: | 2022-09-29 | by ( Nathaniel Meyersohn | ) edition.cnn.com   time to read: +3 min
New York CNN Business —We have all heard of Band-Aid, Tylenol, Benadryl and Johnson’s baby powder. We have never heard of the new made-up word Kenvue. But Kenvue will be the new corporate parent of these familiar consumer health brands next year. The name Kenvue reflects J&J’s desire for the new consumer company identity to take a backseat to well-known brands such as Band-Aid. Then there have been brands that changed their names to signal strategy shifts, such as Dunkin’ dropping “Donuts” in 2018.
0 next >>
Total: 13